🇺🇸 PD0332991 in United States

21 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 21

Most-reported reactions

1. Fatigue — 3 reports (14.29%)
2. Abdominal Pain — 2 reports (9.52%)
3. Asthenia — 2 reports (9.52%)
4. Back Pain — 2 reports (9.52%)
5. Condition Aggravated — 2 reports (9.52%)
6. Contusion — 2 reports (9.52%)
7. Haemoglobin Decreased — 2 reports (9.52%)
8. Heart Rate Increased — 2 reports (9.52%)
9. Hypercalcaemia — 2 reports (9.52%)
10. Musculoskeletal Pain — 2 reports (9.52%)

Source database →

Frequently asked questions

Is PD0332991 approved in United States?

PD0332991 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for PD0332991 in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.